The tetrahydroisoquinoline derivative SB269,652 is an allosteric antagonist at dopamine D3 and D2 receptors

Molecular Pharmacology

Volumn 78, Issue 5, 2010, Pages 925-934

  Silvano, Elena ^a   Millan, Mark J ^b   La Cour, Clotilde Mannoury ^b   Han, Yang ^c   Duan, Lihua ^c   Griffin, Suzy A ^d   Luedtke, Robert R ^d   Aloisi, Gabriella ^a   Rossi, Mario ^a   Zazzeroni, Francesca ^a   Javitch, Jonathan A ^c   Maggio, Roberto ^a  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b INSTITUT DE RECHERCHES INTERNATIONALES SERVIER   (France)

^c Department of Neurology and the Taub Institute for Research on Alzheimer's Disease and the Aging Brain   (United States)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1H INDOLE 2 CARBOXYLIC ACID[4 [2 (CYANO 3,4 DIHYDRO 1H ISOQUINOLIN 2 YL)ETHYL]CYCLOHEXYL]AMIDE; AEQUORIN; BETA ARRESTIN 2; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR; DOPAMINE 3 RECEPTOR BLOCKING AGENT; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; QUINPIROLE; RADIOLIGAND; SPIPERONE; TETRAHYDROISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; ENZYME PHOSPHORYLATION; IC 50; NONHUMAN; PRIORITY JOURNAL;

ALLOSTERIC REGULATION; ANIMALS; ARRESTINS; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; CRICETULUS; DOPAMINE; HUMANS; INDOLES; ISOQUINOLINES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; PROTEIN TRANSPORT; QUINPIROLE; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; TETRAHYDROISOQUINOLINES;

EID: 77958134183     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.110.065755     Document Type: Article

References (42)

1. 3 dopamine receptor. J Recept Signal Transduct Res 24:117-130.
2. 1 transmembrane chimeras. Mol Pharmacol 54:379-388.
3. Ballesteros JA, Shi L, and Javitch JA (2001) Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. Mol Pharmacol 60:1-19. (Pubitemid 32595228)
4. Barak LS, Ferguson SS, Zhang J, and Caron MG (1997) A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem 272:27,497-27,500.
5. Beaulieu JM, Gainetdinov RR, and Caron MG (2009) Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol 49:327-347.
6. 3 receptors for the activation of extracellular signal-regulated kinase. J Biol Chem 279:28304-28314.
7. Blanpain C, Lee B, Vakili J, Doranz BJ, Govaerts C, Migeotte I, Sharron M, Dupriez V, Vassart G, Doms RW, et al. (1999) Extracellular cysteines of CCR5 are required for chemokine binding, but dispensable for HIV-1 coreceptor activity. J Biol Chem 274:18902-18908.
8. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
9. Christopoulos A and Kenakin T (2002) G protein-coupled receptor allosterism and complexing. Pharmacol Rev 54:323-374.
10. Conklin BR, Farfel Z, Lustig KD, Julius D, and Bourne HR (1993) Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha. Nature 363:274-276. (Pubitemid 23158533)
11. Cullen BR (1987) Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol 152:684-704.
12. Cussac D, Newman-Tancredi A, Pasteau V, and Millan MJ (1999) Human dopamine D(3) receptors mediate mitogen-activated protein kinase activation via a phosphatidylinositol 3-kinase and an atypical protein kinase C-dependent mechanism. Mol Pharmacol 56:1025-1030.
13. DeWire SM, Ahn S, Lefkowitz RJ, and Shenoy SK (2007) β-Arrestins and cell signaling. Annu Rev Physiol 69:483-510.
14. Ehlert FJ (1988) Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol Pharmacol 33:187-194.
15. Kendall RT and Luttrell LM (2009) Diversity in arrestin function. Cell Mol Life Sci 66:2953-2973.
16. Han Y, Moreira IS, Urizar E, Weinstein H, and Javitch JA (2009) Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation. Nat Chem Biol 5:688-695.
17. 2 dopamine receptors by amiloride and amiloride analogs. Mol Pharmacol 50:1295-1308.
18. Lazareno S and Birdsall NJ (1995) Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: interaction of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 48:362-378.
19. 2 heterodimers by the antiparkinsonian agents, S32504, pramipexole and ropinirole. J Neurochem 87:631-641.
20. May LT, Leach K, Sexton PM, and Christopoulos A (2007) Allosteric modulation of G protein-coupled receptors. Annu Rev Pharmacol Toxicol 47:1-51.
21. Matsui H, Lazareno S, and Birdsall NJ (1995) Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis. Mol Pharmacol 47:88-98.
22. 3-receptors: II. Functional and behavioral profile compared with GR218,231 and L741,626. J Pharmacol Exp Ther 293:1063-1073.
23. 2 receptors: I. Cellular, electrophysiological, and neurochemical profile in comparison with ropinirole. J Pharmacol Exp Ther 309:903-920.
24. 2 receptors in the control of locomotor activity: a combined behavioural and neurochemical analysis with novel, selective antagonists in rats. Psychopharmacology 174:341-357.
25. 3-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with Gr218,231 and L741,626. J Pharmacol Exp Ther 293:1048-1062.
26. 2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther 324:587-599.
27. 2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 318:810-818.
28. Neve KA, Seamans JK, and Trantham-Davidson H (2004) Dopamine receptor signaling. J Recept Signal Transduct Res 24:165-205.
29. 35S]thio)-triphosphate binding and antibody study. Mol Pharmacol 55:564-574.
30. Ott MC, Mishra RK, and Johnson RL (1996) Modulation of dopaminergic neurotransmission in the 6-hydroxydopamine lesioned rotational model by peptidomimetic analogues of L-prolyl-L-leucyl-glycinamide. Brain Res 737:287-291.
31. Prilla S, Schrobang J, Ellis J, Höltje HD, and Mohr K (2006) Allosteric interactions with muscarinic acetylcholine receptors: complex role of the conserved tryptophan M2422Trp in a critical cluster of amino acids for baseline affinity, subtype selectivity, and cooperativity. Mol Pharmacol 70:181-193.
32. 3 receptor antagonist, SB-277011-A. J Pharmacol Exp Ther 294:1154-1165.
33. Rung JP, Rung E, Helgeson L, Johansson AM, Svensson K, Carlsson A, and Carlsson ML (2008) Effects of (-)-OSU6162 and ACR16 on motor activity in rats, indicating a unique mechanism of dopaminergic stabilization. J Neural Transm 115:899-908.
34. Schetz JA (2005) Allosteric modulation of dopamine receptors. Mini Rev Med Chem 5:555-561.
35. 2-like dopamine receptors through distinct molecular mechanisms. J Pharmacol Exp Ther 289:956-964.
36. Shi L and Javitch JA (2002) The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. Annu Rev Pharmacol Toxicol 42:437-467. (Pubitemid 34162546)
37. 2 receptor lines the binding-site crevice. Proc Natl Acad Sci USA 101:440-445.
38. 3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol Disord Drug Targets 5:25-43.
39. Tamminga CA and Carlsson A (2002) Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis. Curr Drug Targets CNS Neurol Disord 1:141-147.
40. 3 receptor antagonist in vitro and in vivo. J Eur Coll Neuropsychopharmacol 9:S266.
41. Verma V, Mann A, Costain W, Pontoriero G, Castellano JM, Skoblenick K, Gupta SK, Pristupa Z, Niznik HB, Johnson RL, et al. (2005) Modulation of agonist binding to human dopamine receptor subtypes by L-prolyl-L-leucyl-glycinamide and a peptidomimetic analog. J Pharmacol Exp Ther 315:1228-1236. (Pubitemid 41635411)
42. 1 receptor signaling. J Neurosci 20:RC91.